Representative George Whitesides (D-California) recently sold shares of Medtronic plc NYSE: MDT. In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $50,001 and $100,000 in Medtronic stock on March 24th. The trade occurred in the Representative's "GEORGE WHITESIDES INDIVIDUAL" account.
Representative George Whitesides also recently made the following trade(s):
- Sold $100,001 - $250,000 in shares of Netflix NASDAQ: NFLX on 3/27/2025.
- Sold $250,001 - $500,000 in shares of Innoviva NASDAQ: INVA on 3/25/2025.
- Sold $50,001 - $100,000 in shares of Union Pacific NYSE: UNP on 3/24/2025.
- Sold $100,001 - $250,000 in shares of Linde NASDAQ: LIN on 3/24/2025.
- Sold $100,001 - $250,000 in shares of Procter & Gamble NYSE: PG on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Sandoz Group OTCMKTS: SDZNY on 3/24/2025.
- Sold $15,001 - $50,000 in shares of American Electric Power NASDAQ: AEP on 3/24/2025.
- Sold $100,001 - $250,000 in shares of McDonald's NYSE: MCD on 3/24/2025.
- Sold $15,001 - $50,000 in shares of Bank of America NYSE: BAC on 3/24/2025.
- Sold $15,001 - $50,000 in shares of Diageo NYSE: DEO on 3/24/2025.
Medtronic Price Performance
Medtronic stock traded down $0.18 during midday trading on Monday, reaching $83.98. 4,513,345 shares of the stock traded hands, compared to its average volume of 6,676,670. The stock's fifty day moving average is $88.14 and its 200-day moving average is $87.25. Medtronic plc has a 12 month low of $75.96 and a 12 month high of $96.25. The stock has a market cap of $107.71 billion, a P/E ratio of 25.53, a PEG ratio of 2.22 and a beta of 0.79. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48.
Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, beating analysts' consensus estimates of $1.36 by $0.03. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. The company had revenue of $8.29 billion during the quarter, compared to analyst estimates of $8.33 billion. As a group, equities research analysts anticipate that Medtronic plc will post 5.46 EPS for the current year.
Medtronic Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date was Friday, March 28th. Medtronic's payout ratio is presently 85.11%.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Medtronic by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 124,203,387 shares of the medical technology company's stock worth $9,921,367,000 after purchasing an additional 754,395 shares during the period. Capital Research Global Investors increased its holdings in shares of Medtronic by 1.8% in the 4th quarter. Capital Research Global Investors now owns 33,203,685 shares of the medical technology company's stock valued at $2,652,310,000 after acquiring an additional 571,700 shares during the period. Geode Capital Management LLC raised its position in shares of Medtronic by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 27,056,217 shares of the medical technology company's stock worth $2,155,085,000 after acquiring an additional 574,055 shares in the last quarter. Deutsche Bank AG raised its position in shares of Medtronic by 2.1% in the 4th quarter. Deutsche Bank AG now owns 18,443,640 shares of the medical technology company's stock worth $1,473,278,000 after acquiring an additional 372,168 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Medtronic by 17.8% during the fourth quarter. Invesco Ltd. now owns 15,445,284 shares of the medical technology company's stock valued at $1,233,769,000 after purchasing an additional 2,333,600 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on MDT. Citigroup raised Medtronic from a "neutral" rating to a "buy" rating and raised their price objective for the company from $92.00 to $107.00 in a research note on Tuesday, March 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of Medtronic in a research note on Wednesday, February 19th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $105.00 price objective on shares of Medtronic in a research note on Wednesday, February 19th. Robert W. Baird increased their price target on Medtronic from $90.00 to $91.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. Finally, UBS Group increased their price target on Medtronic from $85.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $96.14.
Get Our Latest Stock Report on Medtronic
About Representative Whitesides
George Whitesides (Democratic Party) is a member of the U.S. House, representing California's 27th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Whitesides (Democratic Party) ran for election to the U.S. House to represent California's 27th Congressional District. He won in the general election on November 5, 2024.
George Whitesides earned a bachelor's degree in public and international affairs from Princeton University in 1996 and a master's degree in remote sensing and GIS from the University of Cambridge in 2000. His career experience includes working as the chief of staff for NASA during the administration of President Barack Obama (D) and the CEO of human spaceflight company Virgin Galactic. Whitesides co-founded Megafire Action, an organization dedicated to responding to wildfires. Whitesides co-chaired the Antelope Valley Covid-19 Task Force and joined the Antelope Valley Economic Development and Growth Enterprise (AV EDGE) as a board member.
Medtronic Company Profile
(
Get Free Report)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
See Also
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
